SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
NEW YORK, March 24, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Columbia on behalf of investors who purchased Mallinckrodt plc (NYSE:MNK) securities between July 14, 2014, and January 18, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/mallinckrodt-plc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Mallinckrodt and its acting President and Chief Executive Officer, Mark Trudeau, misrepresented the efficacy of Mallinckrodt’s business model and its ability to maintain sustainable revenue. Specifically, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that Mallinckrodt engaged in unlawful anticompetitive practices to maintain H.P. Acthar Gel’s (“Acthar”) monopoly status as the only FDA-approved therapeutic preparation of adrenocorticotropic hormone and that Mallinckrodt’s increasing reliance on Medicare and Medicaid meant that the Company’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for the drug by taxpayers.
If you suffered a loss in Mallinckrodt you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/mallinckrodt-plc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
